Literature DB >> 9831402

Thrombophilia and inflammatory bowel disease: does factor V mutation have a role?

H H Over1, S Ulgen, T Tuğlular, A Tezel, E Avşar, G Geyik, S Başgül, N Sayhan, N Ulusoy, C Kalayci, N Tözün.   

Abstract

BACKGROUND: An increased tendency for thromboembolism is a well known problem of inflammatory bowel disease (IBD). Microvascular thrombosis has also been claimed as a pathogenic factor in IBD. Recently a point mutation in the gene coding factor V (FV Leiden) has been identified in various thromboembolic diseases, but the role in IBD is unknown.
OBJECTIVE: To determine the frequency of FV Leiden in IBD patients and compare with a group of controls.
METHODS: Sixty-three IBD patients [43 ulcerative colitis (UC) patients and 20 Crohn's disease (CD) patients] and 36 healthy controls were included in the study. Only one of the UC patients had a history of cerebral thromboembolism. The extracted DNA from frozen blood was subjected to polymerase chain reaction for the amplification of FV gene. The amplicons were hybridized both with the mutant and wild-type probes to detect FV mutation. Readings of optical density above 0.3 were considered as positive results. According to the patterns of ELISA, heterozygosity and homozygosity for normal and mutant alleles were determined.
RESULTS: Eight (18%) of UC patients were heterozygous normal and one (2%) patient had homozygous mutation. Eight (45%) of the 20 CD patients had a heterozygous pattern and one (5%) had a homozygous pattern. In the control group four (11%) subjects showed a heterozygous genotype. FV Leiden was found to be statistically more frequent in CD patients (P < 0.005) (odds ratio 6.5, 95% confidence interval 1.3-18.), but not in the UC patients as compared with controls (P> 0.05). There was no significant correlation between FV Leiden presence and disease activity, gender or disease duration for both UC and CD.
CONCLUSION: The results suggest that FV Leiden is more frequent in CD patients, but not in the UC patients as compared with controls. The high rate of factor V mutation in our CD patients suggests the need for further studies to confirm a relationship between this mutation and aetiology of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831402     DOI: 10.1097/00042737-199810000-00002

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

1.  Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications.

Authors:  N Mahmud; A Molloy; J McPartlin; R Corbally; A S Whitehead; J M Scott; D G Weir
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey.

Authors:  Serif Yilmaz; Kadim Bayan; Yekta Tüzün; Sabri Batun; Abdullah Altintaş
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

Review 3.  Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Jie Liang; Shengjun Wu; Bin Feng; Shaoni Lei; Guanhong Luo; Jingbo Wang; Kai Li; Xiaohua Li; Huahong Xie; Dexin Zhang; Xin Wang; Kaichun Wu; Danmin Miao; Daiming Fan
Journal:  J Gastroenterol       Date:  2011-07-30       Impact factor: 7.527

4.  Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis.

Authors:  M Vecchi; E Sacchi; S Saibeni; G Meucci; L Tagliabue; F Duca; R De Franchis
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

5.  Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia.

Authors:  Bas Oldenburg; Bas A C Van Tuyl; René van der Griend; Rob Fijnheer; Gerard P van Berge Henegouwen
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 6.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

7.  Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease.

Authors:  Maha M Maher; Somaya H Soloma
Journal:  Saudi J Gastroenterol       Date:  2008-10       Impact factor: 2.485

8.  Coagulation parameters in inflammatory bowel disease.

Authors:  Can Dolapcioglu; Aliye Soylu; Tulin Kendir; Ali Tuzun Ince; Hatice Dolapcioglu; Sevim Purisa; Cengiz Bolukbas; Haci Mehmet Sokmen; Remzi Dalay; Oya Ovunc
Journal:  Int J Clin Exp Med       Date:  2014-05-15

Review 9.  Inflammatory bowel disease and thrombosis.

Authors:  Ahmet Tezel; Muzaffer Demir
Journal:  Turk J Haematol       Date:  2012-06-05       Impact factor: 1.831

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.